C4’s Adam Crystal to head R&D at Tango

Adam Crystal became president of R&D at Tango Therapeutics Inc. (NASDAQ:TNGX), a precision cancer medicine company. Crystal was CMO of C4 Therapeutics Inc. (NASDAQ:CCCC) and held multiple roles in the oncology division at Novartis Institutes for BioMedical Research. Tango is enrolling patients in the dose escalation study of its first clinical trial and plans to advance three other programs into the clinic over the coming year.

Neurodegenerative disease company BioArctic AB (SSE:BIOA B) hired Anders Martin-Löf as CFO, effective June 1.  Martin-Löf was CFO at Oncopeptides AB (SSE:ONCO), Wilson Therapeutics AB and RaySearch Laboratories AB. He succeeds Jan Mattsson, who will become VP of finance, a newly established role at the company...